Dr.. Wang received his B.S. in Chemistry from Peking University in 1986 and his Ph.D. in Chemistry from Case Western Reserve University in 1992. Dr. Wang did his postdoctoral training in drug design at the National Cancer Institute, NIH between1992-1996. Dr. Wang was Assistant Professor at Georgetown University from 1996-2000 and Associate Professor from 2000-2001. Dr. Wang joined the faculty at the University of Michigan Medical School as a tenured Associate Professor in 2001 and was promoted to Professor in 2006. Dr. Wang was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007. Dr. Wang serves as the Co-Director of the Molecular Therapeutics Program at the University of Michigan Comprehensive Cancer Center and is the Director of the Cancer Drug Discovery Program at the University of Michigan.
Dr. Wang is the Editor-in-Chief for Journal of Medicinal Chemistry, a premier international journal in medicinal chemistry and drug discovery by the American Chemical Society and serves on the editorial board for several international journals.
My primary research interest is the discovery and development of novel small-molecule therapeutics for the treatment of human cancer and other diseases and conditions. I have built a comprehensive drug discovery program at the University of Michigan. My research program consists of three research laboratories. Our computational/informatics laboratory has the expertise in lead identification and lead optimization using structure-based methods and informatics. Our Chemistry laboratory has the capability of synthesizing complex small molecule ligands. Our biology/biochemistry/pharmacology laboratory has the capability and expertise for assay development, in-depth molecular mechanism studies in vitro and in vivo and evaluations of the biological activity of our designed compounds in relevant biochemical assays, cellular models and animal models of human cancer, as well as in vivo pharmacokinetics and pharmacodynamic analysis of our designed compounds in animal models. We have advanced three novel anticancer drugs into Phase I and Phase II human clinical trials and two additional compounds into IND-enabling studies.
Wang S, Bai L, Lu J, Liu L, Yang CY, Sun H. Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics.J Mammary Gland Biol Neoplasia. 2012 Sep 29. [Epub ahead of print]
Chen J, Zhou H, Aguilar A, Liu L, Bai L, McEachern D, Yang CY, Meagher JL, Stuckey JA, Wang S. Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression. J Med Chem. 2012 Oct 11;55(19):8502-14. doi: 10.1021/jm3010306. Epub 2012 Oct 2.
Zhou H, Aguilar A, Chen J, Bai L, Liu L, Meagher JL, Yang CY, McEachern D, Cong X, Stuckey JA, Wang S. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. J Med Chem. 2012 Jul 12;55(13):6149-61. Epub 2012 Jul 2
Brunckhorst MK, Lerner D, Wang S, Yu Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther. 2012 Jul;13(9):804-11. Epub 2012 Jun 6.
Mungamuri SK, Benson EK, Wang S, Gu W, Lee SW, Aaronson SA. p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nat Struct Mol Biol. 2012 Apr 1;19(5):478-84, S1. doi: 10.1038/nsmb.2271.
Zhou H, Chen J, Meagher JL, Yang CY, Aguilar A, Liu L, Bai L, Cong X, Cai Q, Fang X, Stuckey JA, Wang S. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. J Med Chem. 2012 May 24;55(10):4664-82. Epub 2012 May 10. Erratum in: J Med Chem. 2012 Jun 28;55
Bai L, McEachern D, Yang CY, Lu J, Sun H, Wang S. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. Cancer Res. 2012 Mar 1;72(5):1229-38. doi: 10.1158/0008-5472.CAN-11-2428. Epub 2012 Jan 12.
Kawamoto SA, Coleska A, Ran X, Yi H, Yang CY, Wang S. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J Med Chem. 2012 Feb 9;55(3):1137-46. Epub 2012 Jan 24.
Imai A, Zeitlin BD, Visioli F, Dong Z, Zhang Z, Krishnamurthy S, Light E, Worden F, Wang S, Nör JE. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res. 2012 Feb 1;72(3):716-25. Epub 2011 Dec 8.
Peng Y, Sun H, Lu J, Liu L, Cai Q, Shen R, Yang CY, Yi H, Wang S. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. J Med Chem. 2012 Jan 12;55(1):106-14. Epub 2011 Dec 7.